These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 24562604)
41. Ruthenium dendrimers against acute promyelocytic leukemia: Michlewska S; Ionov M; Maroto-Díaz M; Szwed A; Ihnatsyeu-Kachan A; Abashkin V; Dzmitruk V; Rogalska A; Denel M; Gapinska M; Shcharbin D; Gomez Ramirez R; de la Mata FJ; Bryszewska M Future Med Chem; 2019 Jul; 11(14):1741-1756. PubMed ID: 31287722 [TBL] [Abstract][Full Text] [Related]
42. A novel ruthenium(II) arene based intercalator with potent anticancer activity. Ruiz J; Vicente C; de Haro C; Bautista D Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164 [TBL] [Abstract][Full Text] [Related]
43. Ruthenium polypyridyl complexes and their modes of interaction with DNA: is there a correlation between these interactions and the antitumor activity of the compounds? Corral E; Hotze AC; den Dulk H; Leczkowska A; Rodger A; Hannon MJ; Reedijk J J Biol Inorg Chem; 2009 Mar; 14(3):439-48. PubMed ID: 19085018 [TBL] [Abstract][Full Text] [Related]
44. Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and II. Kou JF; Qian C; Wang JQ; Chen X; Wang LL; Chao H; Ji LN J Biol Inorg Chem; 2012 Jan; 17(1):81-96. PubMed ID: 21858685 [TBL] [Abstract][Full Text] [Related]
45. Complexation with organometallic ruthenium pharmacophores enhances the ability of 4-anilinoquinazolines inducing apoptosis. Zheng W; Luo Q; Lin Y; Zhao Y; Wang X; Du Z; Hao X; Yu Y; Lü S; Ji L; Li X; Yang L; Wang F Chem Commun (Camb); 2013 Nov; 49(87):10224-6. PubMed ID: 23856988 [TBL] [Abstract][Full Text] [Related]
46. Histone-deacetylase-targeted fluorescent ruthenium(II) polypyridyl complexes as potent anticancer agents. Ye RR; Ke ZF; Tan CP; He L; Ji LN; Mao ZW Chemistry; 2013 Jul; 19(31):10160-9. PubMed ID: 23828334 [TBL] [Abstract][Full Text] [Related]
48. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888 [TBL] [Abstract][Full Text] [Related]
49. Synthesis, characterization, cellular uptake and apoptosis-inducing properties of two highly cytotoxic cyclometalated ruthenium(II) β-carboline complexes. Chen J; Peng F; Zhang Y; Li B; She J; Jie X; Zou Z; Chen M; Chen L Eur J Med Chem; 2017 Nov; 140():104-117. PubMed ID: 28923379 [TBL] [Abstract][Full Text] [Related]
50. Dinuclear Organoruthenium Complexes Exhibiting Antiproliferative Activity through DNA Damage and a Reactive-Oxygen-Species-Mediated Endoplasmic Reticulum Stress Pathway. Zhao J; Li S; Wang X; Xu G; Gou S Inorg Chem; 2019 Feb; 58(3):2208-2217. PubMed ID: 30675781 [TBL] [Abstract][Full Text] [Related]
57. Labile ruthenium(ii) complexes with extended phenyl-substituted terpyridyl ligands: synthesis, aquation and anticancer evaluation. Huang H; Zhang P; Chen Y; Ji L; Chao H Dalton Trans; 2015 Sep; 44(35):15602-10. PubMed ID: 26245234 [TBL] [Abstract][Full Text] [Related]
58. Structural basis and anticancer properties of ruthenium-based drug complexed with human serum albumin. Zhang Y; Ho A; Yue J; Kong L; Zhou Z; Wu X; Yang F; Liang H Eur J Med Chem; 2014 Oct; 86():449-55. PubMed ID: 25200980 [TBL] [Abstract][Full Text] [Related]